Clinically Relevant Animal Models of Inflammatory Bowel Disease: Utilizing Classical and Novel Approaches to Evaluate Potential Therapies

Presented By: 
Gregory Lyng

Overview: Crohn’s disease (CD) and Ulcerative Colitis (UC), collectively known as IBD, affect up to 500 per 100,000 individuals in the US, with a significant financial burden estimated at over $1.7 billion/year. Currently, there are no curative therapies available for IBD, only treatments intended to achieve and maintain remission from active flares of inflammation.

As the prevalence of IBD increases, there is an urgency to understand the underlying pathobiology and for researchers to develop new targets and potential therapies to treat/cure the condition. The use of predictive animal models that accurately replicate the human disease state are essential to this process.

This webinar discusses several sophisticated pre-clinical animal models of IBD. Included in this discussion are both the classical, chemically-induced, models, as well as more novel approaches to modeling IBD using immunological based methods (adoptive transfer). We will also discuss novel approaches that can be used to provide clinically relevant and actionable data from the aforementioned disease models.